

Participants with HR(+) and HER-2 (-) Advanced or Metastatic Breast Cancer

1. Pre / Post menopausal women and men
2. Progression on or after prior CDK4/6i either from Advanced or Metastatic as most recent treatment
3. No prior SERD, mTORi, PI3Ki orAKTi, CERANs, PROTACs, or other investigational novel anti-endocrine agents
4. No prior chemotherapy in advanced setting

